Madden Dean R, Cheng Qing, Thiran Shalita, Rajan Shanti, Rigo Frank, Keinänen Kari, Reinelt Stefan, Zimmermann Herbert, Jayaraman Vasanthi
Department of Biochemistry, Dartmouth Medical School, Hanover, New Hampshire 03755, USA.
Biochemistry. 2004 Dec 21;43(50):15838-44. doi: 10.1021/bi048447y.
Upon agonist binding, the bilobate ligand-binding domains of the ionotropic glutamate receptors (iGluR) undergo a cleft closure whose magnitude correlates broadly with the efficacy of the agonist. AMPA (alpha-amino-5-methyl-3-hydroxy-4-isoxazolepropionic acid) and kainate are nonphysiological agonists that distinguish between subsets of iGluR. Kainate acts with low efficacy at AMPA receptors. Here we report that the structure-based mutation L651V converts the GluR4 AMPA receptor into a dual-specificity AMPA/kainate receptor fully activated by both agonists. To probe the stereochemical basis of partial agonism, we have also investigated the correlation between agonist efficacy and a series of vibrational and fluorescence spectroscopic signals of agonist binding to the corresponding wild-type and mutant GluR4 ligand-binding domains. Two signals track the extent of channel activation: the maximal change in intrinsic tryptophan fluorescence and the environment of the single non-disulfide bonded C426, which appears to probe the strength of interactions with the ligand alpha-amino group. Both of these signals arise from functional groups that are poised to detect changes in the extent of channel cleft closure and thus provide additional information about the coupling between conformational changes in the ligand-binding domain and activation of the intact receptor.
离子型谷氨酸受体(iGluR)的双叶配体结合结构域在激动剂结合后会发生裂隙闭合,其程度与激动剂的效力大致相关。AMPA(α-氨基-5-甲基-3-羟基-4-异恶唑丙酸)和海人酸是非生理性激动剂,可区分iGluR的不同亚型。海人酸对AMPA受体的作用效力较低。在此我们报告,基于结构的L651V突变将GluR4 AMPA受体转变为一种双特异性AMPA/海人酸受体,两种激动剂均可使其完全激活。为探究部分激动作用的立体化学基础,我们还研究了激动剂效力与一系列激动剂与相应野生型和突变型GluR4配体结合结构域结合的振动和荧光光谱信号之间的相关性。有两个信号可追踪通道激活程度:内在色氨酸荧光的最大变化以及单个非二硫键连接的C426的环境,后者似乎可探测与配体α-氨基相互作用的强度。这两个信号均来自易于检测通道裂隙闭合程度变化的官能团,因此可提供有关配体结合结构域构象变化与完整受体激活之间偶联的额外信息。